Owner Operator Developer Technology licensor
Seqens is a France‑headquartered chemical and pharmaceutical manufacturer operating as a global contract development and manufacturing organization (CDMO). The company develops and produces active pharmaceutical ingredients (APIs), advanced intermediates, and high‑purity specialty chemicals, supporting customers from route design and process development through clinical and commercial supply. Its network of GMP and non‑GMP facilities and R&D centers spans Europe, North America, and Asia, with quality systems aligned to major regulatory requirements.
Alongside small‑molecule drug substances, Seqens supplies specialty ingredients for life‑science and industrial markets, including personal care and health & nutrition. Core services cover custom synthesis, process optimization and scale‑up, multi‑step organic synthesis, purification, and comprehensive analytical and regulatory support. The company emphasizes reliable, traceable, and compliant manufacturing with a focus on supply chain security and responsiveness to customer needs.
Also known as SEQENS SAS, SEQENS, and CELLforCURE by SEQENS.
chemXplore tracks 4 projects involving Seqens, of which one is active.
Besides this one, the record holds 3 completed projects.
Closest to start-up first.
The 3 that are completed, on hold or cancelled are in the record. See all 4 in chemXplore →
Agreement in principle with creditors to deleverage the balance sheet, convert senior lenders into shareholders and preserve operations; completion expected by end of 2026.
Seeking buyer to preserve cell & gene therapy manufacturing after funding slowdown, project cancellations and US relocation. Takeover sought in coming months; employee support prioritized.
The sale aligns with SEQENS' focus on core activities, while Solabia's expertise supports the Limoges site's growth in personal care and life sciences.
The partnership enhances non-GMP intermediates' availability in Europe, ensuring quality, traceability, and quick market response.
The agreement covers 30+ intermediates, enhancing portfolio for API synthesis, ensuring quality, flexibility, and secure supply chain in Europe.
Continuous-flow, lower-footprint paracetamol process; 15,000 t/yr from end‑2026; backed by France 2030 with UPSA and Opella as partners.
The partnership enhances global CDMO capacity, offering integrated services for ATMP development and manufacturing, leveraging expertise and infrastructure across the U.S. and Europe.
The partnership enables PEKK production for long-term medical implants, leveraging expertise in polymer synthesis and global distribution networks.
active all projects
What each is building and closing, and the pipelines and grids between them, on one map.
